Millions of Medicare beneficiaries struggling with obesity will soon have a more affordable path to treatment. Novo Nordisk announced that starting July 1 eligible patients will be able to access Wegovy® (semaglutide) for a monthly copay of just $50 through the newly established Medicare GLP-1 Bridge.
The program, announced in coordination with the Centers for Medicare & Medicaid Services (CMS), aims to close the coverage gap for older Americans. While Medicare Part D has historically faced restrictions regarding weight-loss medications, this “Bridge” initiative specifically targets obesity management, providing access to both the injectable and tablet formulations of the drug.
- Affordability: Flat $50 monthly copay for eligible Medicare patients.
- Full Range: Covers all dosages of both Wegovy® injections and the newly available Wegovy® pills.
- Timeline: The program launches July 1 and is scheduled to run through the end of 2027.
- National Reach: Available across all U.S. states and territories.
Obesity affects a significant portion of the 65-and-older population, often compounding other chronic conditions. Wegovy® is currently the only FDA-approved weight management medication proven to reduce the risk of major cardiovascular events—such as heart attack, stroke, or death—in adults with known heart disease.
“Obesity is a serious, common chronic disease facing older Americans,” Jamey Millar, executive vice president of US Operations for Novo Nordisk said. “We welcome the Medicare GLP-1 Bridge as an important step in getting Wegovy® to more patients… to help eligible seniors access the care they need and deserve.”
The “Bridge” program specifically addresses obesity treatment, but Wegovy® remains available through standard Medicare Part D benefits for other FDA-approved indications, such as reducing cardiovascular risk in patients who are overweight or have established heart disease.
Novo Nordisk confirmed they are working closely with pharmacists, healthcare providers, and patient advocacy groups to ensure a smooth rollout on July 1.
Wegovy® (semaglutide) is a GLP-1 receptor agonist designed for chronic weight management alongside a reduced-calorie diet and increased physical activity. While highly effective, it does carry risks of serious side effects, including potential thyroid tumors and pancreatitis. Patients are encouraged to consult with their healthcare provider to determine eligibility and discuss the full safety profile.
For more information on eligibility and enrollment, beneficiaries can visit CMS.gov or NovoCare.com.
